PETALUMA, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced publication of an open-label pilot study in which a Microcyn® Technology-based antipruritic hydrogel was evaluated in the treatment of atopic dermatitis. The study, appearing in the August 2012 issue of Cutis ( 2012;90:97-102), evaluated the effectiveness of Microcyn-based Atrapro™ antipruritic hydrogel in reducing the itch and clinical signs of atopic dermatitis when applied to affected areas of the body at least three times daily. A reduction in itch as early as day 3 was reported by 14 of 17 patients. At day 14 (end of the study), 82% and 88% of subjects experienced itch reduction according to patient and investigator assessments, respectively. By day 14 the overall body surface area of disease involvement was reduced on average by 58% from the baseline. This impact on the overall disease was also confirmed by the overall global assessment of the atopic dermatitis by the doctor. Mild dryness encountered by some patients readily resolved with emollient use.
Oculus licensed the Microcyn Technology-based products for treatment of atopic dermatitis in the United States to Quinnova Pharamceuticals in February 2011. The lead product, branded as Atrapro™ Antipruritic Hydrogel, was introduced to U.S. dermatologists in February 2012.
"The results of this study are consistent with the feedback we are receiving from dermatologists who have been using Atrapro since its introduction six months ago," said Jeffery Day, president of Quinnova Pharmaceuticals. "The physicians are enthused about the relatively rapid reduction in itch. As well, they appreciate the safety profile of Atrapro—without a single report of any serious adverse effects. Typically, atopic dermatitis treatments provide one or the other—some degree of efficacy or some degree of safety—but seldom both as is the case with Atrapro hydrogel."An abstract of the Cutis study can be found at: http://www.cutis.com/Article.aspx?ArticleId=c4dYnsdSxNM= About Atopic Dermatitis More than 15 million patients have symptoms of atopic dermatitis, characterized by itchy skin, which can lead to rash, redness, swelling, crusting and scaling. The disease affects up to 20 percent of infants and young children, who continue to have symptoms as adults with significant impact on their quality of life. The exact cause is unknown, but genetics are considered a key factor.